Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma.
BACKGROUND
Pheochromocytomas are rare catecholamine-producing tumors derived in more than 30% of cases from mutations in 9 tumor-susceptibility genes identified to date, including von Hippel-Lindau tumor suppressor (VHL); succinate dehydrogenase complex, subunit B, iron sulfur (Ip) (SDHB); and succinate dehydrogenase complex, subunit D, integral membrane protein (SDHD). Testing of multiple genes is often undertaken at considerable expense before a mutation is detected. This study assessed whether measurements of plasma metanephrine, normetanephrine, and methoxytyramine, the O-methylated metabolites of catecholamines, might help to distinguish different hereditary forms of the tumor.


METHODS
Plasma concentrations of O-methylated metabolites were measured by liquid chromatography with electrochemical detection in 173 patients with pheochromocytoma, including 38 with multiple endocrine neoplasia type 2 (MEN 2), 10 with neurofibromatosis type 1 (NF1), 66 with von Hippel-Lindau (VHL) syndrome, and 59 with mutations of SDHB or SDHD.


RESULTS
In contrast to patients with VHL, SDHB, and SDHD mutations, all patients with MEN 2 and NF1 presented with tumors characterized by increased plasma concentrations of metanephrine (indicating epinephrine production). VHL patients usually showed solitary increases in normetanephrine (indicating norepinephrine production), whereas additional or solitary increases in methoxytyramine (indicating dopamine production) characterized 70% of patients with SDHB and SDHD mutations. Patients with NF1 and MEN 2 could be discriminated from those with VHL, SDHB, and SDHD gene mutations in 99% of cases by the combination of normetanephrine and metanephrine. Measurements of plasma methoxytyramine discriminated patients with SDHB and SDHD mutations from those with VHL mutations in an additional 78% of cases.


CONCLUSIONS
The distinct patterns of plasma catecholamine O-methylated metabolites in patients with hereditary pheochromocytoma provide an easily used tool to guide cost-effective genotyping of underlying disease-causing mutations.
Institute of Clinical Chemistry and Laboratory Medicine, Department of Medicine III, University of Dresden, Dresden, Germany. Graeme.Eisenhofer@uniklinikum-dresden.de
Graeme
G
Eisenhofer
Jacques W M
JW
Lenders
Henri
H
Timmers
Massimo
M
Mannelli
Stefan K
SK
Grebe
Lorenz C
LC
Hofbauer
Stefan R
SR
Bornstein
Oliver
O
Tiebel
Karen
K
Adams
Gennady
G
Bratslavsky
W Marston
WM
Linehan
Karel
K
Pacak
D000310:Adrenal Gland Neoplasms / Q000097:blood / Q000235:genetics; D014408:Biomarkers, Tumor / Q000097:blood* / Q000652:urine; D003937:Diagnosis, Differential; D004298:Dopamine / Q000031:analogs & derivatives* / Q000097:blood / Q000652:urine; D006801:Humans; D008676:Metanephrine / Q000097:blood* / Q000652:urine; D009386:Neoplastic Syndromes, Hereditary / Q000097:blood / Q000235:genetics; D009647:Normetanephrine / Q000097:blood* / Q000652:urine; D010673:Pheochromocytoma / Q000097:blood / Q000235:genetics; D012189:Retrospective Studies
D014408:Biomarkers, Tumor; D009647:Normetanephrine; D008676:Metanephrine; C001746:3-methoxytyramine; D004298:Dopamine
J Clin Endocrinol Metab. 2009 May;94(5):1701-5
19258401
Clin Chem. 1986 Nov;32(11):2030-3
3096593
J Clin Endocrinol Metab. 2001 May;86(5):1999-2008
11344198
Ann N Y Acad Sci. 2006 Aug;1073:156-65
17102082
J Clin Endocrinol Metab. 2007 Mar;92(3):779-86
17200167
J Clin Endocrinol Metab. 2006 Aug;91(8):2851-8
16735498
Cancer Res. 2009 Apr 15;69(8):3650-6
19351833
J Clin Endocrinol Metab. 2009 Aug;94(8):2677-83
19657044
J Natl Cancer Inst. 2003 Aug 20;95(16):1196-204
12928344
Ann N Y Acad Sci. 2006 Aug;1073:94-103
17102076
Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):92-102
17237836
JAMA. 2002 Mar 20;287(11):1427-34
11903030
J Clin Endocrinol Metab. 2005 Apr;90(4):2068-75
15644397
N Engl J Med. 1999 Jun 17;340(24):1872-9
10369850
Hum Mol Genet. 2010 Aug 1;19(15):3011-20
20484225
Ann N Y Acad Sci. 2006 Aug;1073:104-11
17102077
N Engl J Med. 2002 May 9;346(19):1459-66
12000816
Hum Pathol. 2010 Jun;41(6):805-14
20236688
Clin Chem. 1993 Jan;39(1):97-103
8419068
J Med Genet. 2007 Sep;44(9):586-7
17557926
Clin Chem. 2009 Dec;55(12):2223-4
19833834
Lancet Oncol. 2009 Aug;10(8):764-71
19576851
J Clin Oncol. 2005 Dec 1;23(34):8812-8
16314641
Lancet Oncol. 2010 Apr;11(4):366-72
20071235
Clin Chem. 2005 Apr;51(4):735-44
15718487
Nat Genet. 2010 Mar;42(3):229-33
20154675
Ann Clin Biochem. 2010 Mar;47(Pt 2):137-42
20144968
Lancet. 2005 Aug 20-26;366(9486):665-75
16112304
J Clin Endocrinol Metab. 1998 Jun;83(6):2175-85
9626157
J Clin Endocrinol Metab. 2006 Nov;91(11):4505-9
16912137
J Clin Endocrinol Metab. 2009 May;94(5):1541-7
19223516